44 articles for BP Roques
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and biological activity of CCK26-33-related analogues modified in position 31.
University of Paris
Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
Pharmaleads
New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
Pharmaleads
Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.
University of Paris
Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.
University of Paris
Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach.
University of Paris
Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme.
University of Paris
Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
University of Paris
Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
University of Paris
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
University of Paris
Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
University of Paris
Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors.
University of Paris
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
University of Paris
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
University of Paris
Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.
University of Paris
Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes.
Ua 498 Cnrs
Investigation of the structural parameters involved in the mu and delta opioid receptor discrimination of linear enkephalin-related peptides.
University of Paris
New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties.
TBA
New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
TBA
Evidence of the preferential involvement of mu receptors in analgesia using enkephalins highly selective for peripheral mu or delta receptors.
TBA
Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor.
University of Paris
Structure-based design and pharmacological properties of potent selective and systemically active CCK-B peptidomimetics
TBA
N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
University of Paris
Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain.
University of Paris
Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid.
University of Paris
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
University of Paris
Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties.
University of Paris
Synthesis and structure-activity studies of a series of [(hydroxybenzyl)amino]salicylates as inhibitors of EGF receptor-associated tyrosine kinase activity.
University of Paris
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
University of Paris
Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions.
University of Paris
Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols.
University of Paris
Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives.
University of Paris
1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of"enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition.
TBA
Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for delta opioid receptors.
Ua 498 Cnrs
New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties.
University of Paris
Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
University of Paris
Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue.
University of Paris
Investigation of peripheral cholecystokinin receptor heterogeneity by cyclic and related linear analogues of CCK26-33: synthesis and biological properties.
TBA
Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity.
Hebrew University of Jerusalem
Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists.
University of Paris
